Remedy Alliance is a not-for-profit organization that has become a leading supplier of naloxone to local harm reduction groups—which provide healthcare support for people using drugs who may be otherwise unwilling to engage with the regular health system.  

According to the Centers for Disease Control, opioids like heroin and fentanyl were the largest contributing factor in more than 100,000 overdose deaths in the United States last year, a worsening of the overdose crisis that the federal government declared a national health care emergency in 2017.     

The aggressive distribution of naloxone—available without medical prescription—has been credited with lowering overdose deaths across the country. SEDF is providing Remedy Alliance a low-cost $1 million loan to support its response to the arrival on the market of a new branded nasal spray version of naloxone, approved by the Food and Drug Administration in March 2023. Remedy Alliance is working with a generic manufacturer to produce a lower cost version that it can sell at significantly lower prices to institutions, sustaining the delivery of free doses to underfunded harm reduction groups.  

Remedy Alliance will use SEDF’s loan to launch disbursement of the new nasal naloxone product RiVive™ and will expand its distribution channels to reach more people affected by the overdose crisis directly through harm reduction programs, who are working directly with people who use drugs. The loan will allow Remedy Alliance to expand its offerings to intranasal naloxone developed by the nonprofit pharmaceutical company Harm Reduction Therapeutics. Remedy Alliance will manage Harm Reduction Therapeutics‘ robust donation program as well as selling RiVive™ at a lower cost than other nasal naloxone products.   

This investment will make it easier and more affordable for communities in the United States to access naloxone and contribute to the prevention of overdose-related morbidity and deaths.  

• People who use drugs are better able to access naloxone when they need it most.
• The investment will support a more consistent, affordable, and diverse supply of naloxone to Harm Reduction Programs.

This investment in Remedy Alliance is part of Open Society Foundations ongoing response to the opioid epidemic in the United States.